Precocious Puberty News and Research

RSS

No adulthood metabolic consequences of central precocious puberty

Researchers have found that girls with central precocious puberty have similar metabolic and general health to other women when they reach young to middle adulthood.

13 Mar 2015

Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

With just one month until 2014 Biotech China, experts, entrepreneurs and decision-makers from the international biotechnology industry will gather at the heart of the Chinese biotechnology industry on May 14-16th, 09:00 AM-06:00 PM in Nanjing China.

10 Apr 2014

Study: Vitamin D supplementation may help delay early onset of puberty in girls

Vitamin D supplementation may help delay early onset of puberty in girls, a new clinical study finds. The results were presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

18 Jun 2013

Neurosurgeons remove hypothalamic hamartoma to combat hyperphagia, unhealthy weight gain

Neurosurgeons at the University of Texas-Houston and Children's Memorial Hermann Hospital (Houston, Texas) report on the success they achieved when they removed a hypothalamic hamartoma from a 10-year-old girl to combat hyperphagia (excessive appetite and compulsive overeating) and consequent unhealthy weight gain.

10 Apr 2013

Insight into reasons why precocious puberty occurs in females

New research from Oregon Health & Science University has provided significant insight into the reasons why early-onset puberty occurs in females.

30 Jan 2013

ARCHITECT 2nd Generation Testosterone Assay from Abbott

Testosterone is an important androgen hormone in the health and well-being of men and women. Testosterone levels are associated with sexual development, libido, protection against osteoporosis, and cardiovascular health. In men, insufficient testosterone levels (hypogonadism) have been linked to obesity and low libido.

18 Dec 2012

Debiopharm initiates enrollment in triptorelin phase III study for central precocious puberty

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced that the first patient has been enrolled in an open-label phase III study to investigate the efficacy, safety, and pharmacokinetics of the sustained release triptorelin pamoate 22.5 mg 6-month-formulation in children with central precocious puberty (CPP), a rare disease.

27 Aug 2012

ZEN bust-enhancing supplements may increase risk of breast cancer

Women who use bust-enhancing dietary supplements containing the mycoestrogen zearalenone (ZEN), a naturally occurring toxin that widely contaminates agricultural products, could be increasing their risk of breast cancer. That is the warning from breast health experts in a paper published online ahead of print publication in the January issue of IJCP, the International Journal of Clinical Practice.

9 Dec 2011

Epilepsy patients can benefit from gamma knife radiosurgery

Neurosurgeons continue to explore minimally invasive surgery with gamma radiation (gamma knife surgery / GKS) in the treatment of brain lesions causing seizures and epilepsy. Studies of the procedure are showing it to be an effective alternative to invasive microsurgery for hypothalamic hamartomas and other lesions that lie deep within the brain.

5 Dec 2011

Hypothalamus may be involved in generating laughter

Anecdotal evidence suggests that the hypothalamus, a structure lying deep within the brain may be involved in generating laughter. Gelastic epilepsy, a rare condition characterized by laughing seizures, is commonly the result of a congenital brain lesion within the hypothalamus.

5 Dec 2011

FDA approves two new strengths of Lupron Depot-PED for central precocious puberty

Abbott announced today that the U.S. Food and Drug Administration has approved two new strengths for three-month administration of Lupron Depot-PED (leuprolide acetate for depot suspension) for the treatment of children with central precocious puberty (CPP).

17 Aug 2011

Exposure to phthalates can cause children's allergy and asthma

Recent controversy over the discovery of clouding agents containing the banned chemical DEHP in beverages has caused public concerns.

2 Jun 2011

How male puberty begins

Scientists from Monash University have uncovered a new understanding of how male puberty begins.

14 Mar 2011

Debiopharm recognised with European Biopharmaceuticals company of the year award

The 2010 Frost & Sullivan Europe Company of the Year Award in Biopharmaceuticals is presented to Debiopharm Group™ (Debiopharm).

1 Dec 2010

Study suggests less than 10% of UK adults with CAH receive specialist endocrine care

A new study suggests that less than 10% of the estimated 3,591 adults in the UK with the genetic condition congenital adrenal hyperplasia (CAH) receive specialist endocrine care, and that there is no standard treatment for these patients.

26 Nov 2010

LA surgeon develops minimally invasive approach to remove pineal tumors

One of the most difficult-to-remove tumors located deep in the midbrain area can now be safely excised thanks to the work of one Los Angeles surgeon. Hrayr Shahinian, M.D., medical director of The Skull Base Institute in Los Angeles, has developed a minimally invasive approach to removing pineal tumors so called as they are shaped like pine cones.

21 Sep 2010

Endo Pharmaceuticals total revenues for second-quarter 2010 increase 6% to $396.5 million

Endo Pharmaceuticals today reported financial results for the second quarter 2010. Total revenues during the second quarter of 2010 increased 6 percent to $396.5 million, compared with $373.1 million in the same quarter of 2009. Net income for the three months ended June 30, 2010 was $51.5 million, compared with $30.0 million in the comparable 2009 period.

30 Jul 2010

FDA issues advisory on prostate cancer drugs

Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several studies by the U.S. Food and Drug Administration.

3 May 2010

Discovery of inhibitory hormone may yield new treatments for cancer and other diseases

Nearly 10 years after the discovery that birds make a hormone that suppresses reproduction, University of California, Berkeley, neuroscientists have established that humans make it too, opening the door to development of a new class of contraceptive and possible treatments for cancer or other diseases.

23 Dec 2009

Endo Pharmaceuticals to acquire Indevus Pharmaceuticals

Endo Pharmaceuticals (NASDAQ:ENDP) and Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) announced today that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash, and up to an additional approximately $267 million, or $3.00 per Indevus share, in cash payable in the future upon achievement of certain regulatory and sales milestones.

5 Jan 2009